The protective effect of a novel compound RU 18492, on galactosamine-induced hepatotoxicity in the rat.
A novel compound N-(2-hydroxyethyl)-maleopimarimidyl morpholide (RU 18 492), was investigated for its effect against galactosamine induced hepatitis in rats. It was found to be active in reducing both serum transaminase levels and morphological changes due to the hepatotoxin. The protection was shown to be dose related and a significant reduction in liver damage was seen at doses of 50-400 mg/kg p.o. RU 18 492 was ineffective against carbon tetrachloride induced hepatitis in rats. It was suggested that the protective effect of RU 18 492 was due to its ability to stimulate the smooth endoplasmic reticulum thus inducing a more rapid detoxification of galactosamine.
D000818:Animals; D002252:Carbon Tetrachloride Poisoning / Q000188:drug therapy; D056486:Chemical and Drug Induced Liver Injury / Q000188:drug therapy*; D005688:Galactosamine; D008297:Male; D009025:Morpholines / Q000627:therapeutic use*; D051381:Rats; D014315:Triterpenes / Q000627:therapeutic use*
D009025:Morpholines; D014315:Triterpenes; D005688:Galactosamine